{"id":893090,"date":"2025-10-07T07:15:19","date_gmt":"2025-10-07T11:15:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/"},"modified":"2025-10-07T07:15:19","modified_gmt":"2025-10-07T11:15:19","slug":"akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/","title":{"rendered":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th<\/sup> Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY study in patients with pre-cirrhotic (F2-F3) MASH.<\/p>\n

Details for the presentations are as follows:<\/p>\n

\n
\n Oral Presentations<\/u>
\n <\/strong>\n <\/p>\n

\n Title:<\/strong> Efruxifermin was associated with improvements in multiple non-invasive tests indicative of fibrosis regression in participants with compensated cirrhosis due to MASH (SYMMETRY)
Presenter: <\/strong>Vlad Ratziu, M.D., Ph.D., Professor of Hepatology, Sorbonne Universit\u00e9 and the H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re Medical School
Session:<\/strong> Clinical Plenary #1
Date\/Time:<\/strong> Sunday, November 9, 2025, 12:00 PM ET<\/p>\n

\n Title:<\/strong> Efruxifermin improved markers of portal hypertension as evaluated by Baveno VII criteria in compensated cirrhosis due to MASH: results from a 96-week, placebo-controlled, phase 2b trial
Presenter:<\/strong> Mazen Noureddin, M.D., M.H.Sc., Professor of Medicine, Houston Methodist Hospital and Director, Houston Research Institute
Session:<\/strong> MASH Clinical Trials
Date\/Time:<\/strong> Sunday, November 9, 2025, 2:45 PM ET<\/p>\n

\n
\n Poster Presentation<\/u>
\n <\/strong>\n <\/p>\n

\n Title:<\/strong> AI-powered histology analysis of HARMONY reveals Efruxifermin-driven changes in the liver microarchitecture in F2\/F3 MASH
Presenter:<\/strong> J\u00f6rn M. Schattenberg, M.D., Professor of Medicine, Director of the Department of Medicine, Saarland University Medical Center, University of Saarland
Session:<\/strong> MASLD\/MASH Therapeutics: New Agents and Approved \/ Available Agents
Date\/Time:<\/strong> Monday, November 10, 2025, from 11:30 AM-12:30 PM ET<\/p>\n

\n About Akero Therapeutics<\/strong>\n <\/p>\n

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH). Akero\u2019s lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies: SYNCHRONY Histology<\/em> in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, SYNCHRONY Outcomes<\/em> in patients with compensated cirrhosis (F4c) due to MASH, and SYNCHRONY Real-World<\/em> in patients with MASH or MASLD (metabolic dysfunction-associated steatotic liver disease). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. Akero is headquartered in South San Francisco. Visit us at akerotx.com<\/u><\/a> and follow us on LinkedIn<\/u><\/a> and X<\/u><\/a> for more information.<\/p>\n

\n Investor Contact:<\/strong>
\n
Christina Tartaglia
Precision AQ
212.362.1200
IR@akerotx.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Peg Rusconi
Deerfield Group
617.910.6217
Peg.rusconi@deerfieldgroup.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY … <\/p>\n

Continue reading “Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-893090","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAkero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY … Continue reading "Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T11:15:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025\",\"datePublished\":\"2025-10-07T11:15:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/\",\"name\":\"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=\",\"datePublished\":\"2025-10-07T11:15:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/","og_locale":"en_US","og_type":"article","og_title":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two upcoming oral presentations and a poster presentation at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting\u00ae 2025 taking place November 7-11, 2025, in Washington, DC. The presentations will highlight findings from the 96-week Phase 2b SYMMETRY study evaluating the safety and efficacy of lead product candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4c) due to metabolic dysfunction-associated steatohepatitis (MASH), along with insights from an AI-powered digital analysis of histology data from the 96-week Phase 2b HARMONY … Continue reading \"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-07T11:15:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025","datePublished":"2025-10-07T11:15:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/"},"wordCount":483,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/","name":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=","datePublished":"2025-10-07T11:15:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0MTExNSM3MTgyNzQxIzIxODM3NzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akero-therapeutics-to-present-new-data-from-the-phase-2b-symmetry-and-harmony-studies-of-efruxifermin-at-the-76th-annual-aasld-the-liver-meeting-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting\u00ae 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=893090"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/893090\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=893090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=893090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=893090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}